Globe News Wire
02 Mar 2026, 14:47 UTC · 28w ago
Verdict
Headline takes no side. We score CORT −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Corcept Therapeutics' NDA for relacorilant as a treatment for hypercortisolism due to insufficient evidence of effectiveness.
More negative than 98% of claims this week
A federal securities fraud class action lawsuit alleges Corcept officers misled investors by claiming the relacorilant NDA had 'powerful support' despite FDA warnings of adequacy issues.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 86% of claims this week
A securities fraud class action lawsuit against Five9, Inc. has survived a motion to dismiss regarding claims of misrepresented business bookings.
More negative than 72% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
Facing a securities fraud class action lawsuit and an FDA Complete Response Letter rejecting its drug application.
More negative than 87% of ticker scores this week
A securities fraud class action lawsuit against the company has survived a motion to dismiss.
More negative than 72% of ticker scores this week
Named as a subject of investigation by a law office regarding potential breaches of fiduciary duty.
More negative than 72% of ticker scores this week
Named as a subject of investigation by a law office regarding potential breaches of fiduciary duty.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+213.2%
Price is moving against the score
$111.80 vs $35.70 close before publication (Feb 27) · not market-adjusted
CORT chart →
